Clinical trials
CAR clinical trials
Below are recruiting car clinical trials, each written for real people, not researchers. We’re tracking 788 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07162038RecruitingPhase 1
Combining CAR-T cells with a stem cell transplant for blood cancers
This trial tests adding anti-CD19 CAR-T cells to a half-matched stem cell transplant for people with high-risk blood cancers. The goal is to see if this combination is safe and can improve outcomes.
Bethesda, MarylandAges 18–75 - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07328503RecruitingPhase 2
CD22 CAR T-cells to prevent relapse after CD19 CAR T-cell therapy
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
Bethesda, MarylandAges 3–65 - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07480928RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07510828RecruitingPhase 1/Phase 2
CAR-NK cells for advanced solid tumors
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07523542RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Treatment-Resistant Lupus
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Shenzhen, GuangdongAges 18–70 - NCT07627711RecruitingPhase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT05650749Enrolling by invitationPhase 1
GPC2 car T cells for neuroblastoma and retinoblastoma
This trial tests a new treatment using engineered immune cells (CAR T cells) that target a protein called GPC2 found on some cancer cells. It is for patients with high-risk neuroblastoma or metastatic retinoblastoma that has returned or not responded to other treatments.
Philadelphia, PennsylvaniaAges 1 year+ - NCT05477927RecruitingPhase 1
CAR-T therapy for cancers spread to lining of lungs, belly, or brain
This trial tests an experimental CAR-T cell treatment that targets proteins on cancer cells that have spread to the lining of the lungs, belly, or brain. It may help people whose cancer has not responded to standard treatments.
Chengdu, SichuanAges 18–80 - NCT07172958RecruitingPhase 1
Immune cell therapy for children with certain solid tumors
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
Washington D.C., District of ColumbiaAges 1–23 - NCT06318533RecruitingEarly Phase 1
Engineered immune cell therapy for autoimmune diseases
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
Zhenjiang, JiangsuAges 18–70 - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT05544526RecruitingPhase 1
CAR T cell treatment for brainstem spinal cord tumor in children
This Phase 1 trial tests CAR T cells designed to attack a specific target (GD2) on a rare childhood brain/spinal tumor called DMG with a certain gene change (H3K27M). It is mainly designed to check safety and early signs of effectiveness after prior treatments.
LondonAges Up to 16 years - NCT07341191RecruitingPhase 2
Sonrotoclax and zanubrutinib before CAR-T for mantle cell lymphoma
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) given before your planned CAR-T cell therapy. The goal is to see if this approach can help control the lymphoma while you wait for CAR-T.
Edmonton, AlbertaAges 18 years+ - NCT06486051RecruitingPhase 2
CAR T-cell therapy for adults with relapsed large B-cell lymphoma
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
Auckland, AucklandAges 18–75 - NCT06006741RecruitingPhase 1
CAR-T cell therapy for multiple myeloma patients
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
Shenzhen, GuangdongAges 18–80 - NCT05024175Recruiting
Follow-up for people who received CAR T-cell therapy
This study is for people who previously received CAR T cells at the Dana-Farber/Harvard Cancer Center (DF/HCC). It mainly checks how you’re doing over the long term after treatment, and asks you to take part in follow-up visits or procedures.
Boston, MassachusettsAges 18 years+ - NCT05990465RecruitingPhase 1
LV20.19 CAR T-cells plus pirtobrutinib for relapsed B-cell lymphoma
This trial combines a new type of CAR T-cell therapy (LV20.19) with a targeted pill called pirtobrutinib to treat B-cell lymphomas that have come back or stopped responding. The goal is to see if this combination works better than each alone.
Milwaukee, WisconsinAges 18–81 - NCT06992583RecruitingPhase 1
CAR-T cell therapy for advanced CEA-positive lung cancer
This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.
Nanjing, JiangsuAges 18 years+ - NCT06769191RecruitingEarly Phase 1
CD7 car-t, stem cell transplant, and kidney transplant for SIOD
This trial tests a sequence of treatments for SIOD (a genetic condition causing immune and kidney problems). First, you receive CD7 car-t cells, then a stem cell transplant from a family donor, followed by a kidney transplant from the same donor. The goal is to see if this approach is safe and can help your body accept the new kidney.
Hangzhou, ZhejiangAges Any age - NCT06695013RecruitingPhase 2
Maintenance therapy after CAR-T for low-risk B-cell lymphoma
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06560827RecruitingPhase 1
CAR-T Cells for Liver Cancer After Surgery
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
BeijingAges 18–75
Hear when a new CAR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car?
- Yes. Clin2 currently lists 788 recruiting car studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.